Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take

Bristol-Myers Squibb will pay Halozyme $105 million for the right to use the smaller company’s technology to develop easier-to-use versions of its best-selling cancer immunotherapy Opdivo, as well as as many as 11 other drugs in the larger company’s research pipeline.September 14, 2017 at 08:00AM

via Forbes Real Time